Body composition in women
SURMOUNT and SURPASS phase 3 programs included substantial female participation. Researchers have analyzed body weight, fat mass and waist circumference outcomes across female subgroups including post-menopausal cohorts.
Metabolic
Tirz
GLP-1/GIP research
A dual GLP-1 and GIP receptor agonist studied extensively in metabolic, glycemic and weight-regulation research.
$74.99per vial · research use
Quantity
Up to 50%
Dose
- Dual incretin pathway
- Glycemic regulation
- Body composition models
For research use only. Not for human consumption.
Women's research notes
What researchers study Tirz for in women
Tirzepatide clinical research includes large female cohorts, with published trials reporting on body composition, glycemic control and PCOS-adjacent metabolic endpoints.
PCOS & insulin resistance research
Because PCOS is characterized by insulin resistance, dual incretin agonists are referenced in female-specific metabolic literature exploring glycemic and androgenic endpoints.
Appetite & satiety signaling
Tirzepatide research has measured appetite and food-intake endpoints in mixed-sex cohorts, with sub-analyses examining responses across hormonal life stages.
Selected literature
- Jastreboff AM, et al. NEJM 2022 — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
- Frías JP, et al. NEJM 2021 — Tirzepatide versus semaglutide once weekly in type 2 diabetes
Information below summarizes published pre-clinical and clinical research. It is provided for educational purposes for qualified researchers and is not medical advice, a treatment recommendation, or a claim of efficacy. Products are sold for research use only.
